GSK kicks off JPM deal­mak­ing with $1B+ buy­out of IDRx and its rare can­cer drug

Is the fren­zy of JPM deal­mak­ing fi­nal­ly un­der­way?

GSK an­nounced Mon­day morn­ing that it will ac­quire the pri­vate­ly-held biotech IDRx for $1 bil­lion up­front, bring­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER